You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 59 No. 6, June 2002 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (24)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Neurogenetics
 •Movement Disorders
 •Parkinson Disease/ Parkinsonian Disorders
 •Genetic Counseling/ Testing/ Therapy
 •Genetic Disorders
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Molecular Findings in Familial Parkinson Disease in Spain

Janet Hoenicka, PhD; Lídice Vidal, BS; Blas Morales, MD, PhD; Israel Ampuero, BS; F. Javier Jiménez-Jiménez, MD, PhD; Jose Berciano, MD, PhD; Teodoro del Ser, MD, PhD; Adriano Jiménez, MD, PhD; Pedro G. Ruíz, MD, PhD; Justo G. de Yébenes, MD, PhD

Arch Neurol. 2002;59:966-970.

Background  Several genetic errors in {alpha}-synuclein (Park1) and ubiquitin carboxyl-terminal–hydrolase L1(Park5) genes cause autosomal dominant familial Parkinson disease. Mutations in the parkin gene (Park2) are the major cause of autosomal recessive Parkinson disease.

Objective  To analyze the clinical and molecular data of 19 Spanish kindreds (13 with recessive, 4 with dominant, and 2 with uncertain inheritance) who have familial Parkinson disease.

Methods  We searched for the previously described mutations in Park1 and Park5 genes and for new or described mutations in Park2. We used single-strand conformation polymorphism, direct sequencing, and restriction digestion of polymerase chain reaction (PCR)–amplified genomic DNA for this study.

Results  None of these families have either Park1 or Park5 mutations. We found 5 different mutations in Park2 gene in 5 of the families with recessive inheritance. To our knowledge, 2 of these mutations, V56E and C212Y, have not been previously reported. The other mutations found (deletion of exons 3 and 5 and 225delA) have been described in other ethnic groups. Heterozygous carriers of a single Park2 mutation either were asymptomatic or developed clinical symptoms in late adulthood or after brief exposure to haloperidol therapy.

Conclusions  Mutations in Park2 gene account for 38% of the families with recessive parkinsonism in Spain. We found 2 cases of simple heterozygous Park2 mutation carriers that developed clinical symptoms, either in late adulthood or after brief exposure to parkinsonizing agents. Thus, hereditary Parkinson disease has more variable clinical phenotype and molecular defects than previously thought since heterozygous mutations could be a risk factor for parkinsonism.


From the Unidad de Diagnóstico Molecular, Banco de Tejidos para Investigaciones Neurológicas, Madrid (Drs Hoenicka and de Yébenes, Ms Vidal, and Mr Ampuero), Servicios de Neurología, Hospital Universitario S Cecilio, Granada (Dr Morales), Hospital Príncipe de Asturias, Alcalá de Henares (Dr Jiménez-Jiménez), Hospital Severo Ochoa, Leganés (Dr del Ser), Hospital Ramón y Cajal, Madrid, and Hospital Marqués de Valdecilla, Cantabria (Dr Jiménez), and Fundación Jiménez Díaz, Madrid (Drs Berciano, Ruíz, and de Yébenes), Spain.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 2002;59(6):1048-1050.
FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Suppression of Parkin enhances nigrostriatal and motor neuron lesion in mice over-expressing human-mutated tau protein
Menendez et al.
Hum Mol Genet 2006;15:2045-2058.
ABSTRACT | FULL TEXT  

Mutational analysis of the PINK1 gene in early-onset parkinsonism in Europe and North Africa
Ibanez et al.
Brain 2006;129:686-694.
ABSTRACT | FULL TEXT  

Juvenile Parkinson Disease and the C212Y Mutation of Parkin
Ruiz-Linares
Arch Neurol 2004;61:444-444.
FULL TEXT  

Juvenile Parkinson Disease and the C212Y Mutation of Parkin--Reply
Hoenicka
Arch Neurol 2004;61:444-444.
FULL TEXT  

Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse
Itier et al.
Hum Mol Genet 2003;12:2277-2291.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2002 American Medical Association. All Rights Reserved.